Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Faron Pharmaceuticals Oy ( (GB:FARN) ) has provided an update.
Faron Pharmaceuticals has called its Annual General Meeting for 4 May 2026 in Turku, where shareholders will review the 2025 financial statements and other standard governance items. The company’s 2025 losses of EUR 27.2 million are proposed to be carried forward, with the Board recommending that no dividend be paid, underscoring the firm’s ongoing investment and loss-making phase.
The Shareholders’ Nomination Board is proposing to keep Board remuneration unchanged while refining meeting fee structures and maintaining separate additional fees for committee roles. It also seeks to set the Board size at six, re-elect five current directors, appoint Tuomo Pätsi as chair and add biotech deal-making veteran Dr. George Golumbeski, signaling a strategic emphasis on business development expertise.
The Board further proposes reappointing PricewaterhouseCoopers Oy as auditor with Panu Vänskä as key audit partner, ensuring continuity in financial oversight. Crucially, it is asking shareholders for authority to issue up to 40 million new shares and to dispose of a large pool of treasury shares, giving Faron significant flexibility to raise capital or structure strategic transactions in support of its long-term growth plans.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a Finland-based biopharmaceutical company focused on developing innovative treatments, particularly in areas such as oncology and immune modulation. Listed on public markets, it operates in a capital-intensive industry where shareholder approvals for governance, financing authorizations and board composition are central to advancing its clinical and commercial pipeline.
For an in-depth examination of FARN stock, go to TipRanks’ Overview page.